Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Commission consults on new types of fees payable to EMA under EU pharmacovigilance law

This article was originally published in SRA

Executive Summary

The European Commission is seeking feedback on new types of fees that drug companies will have to pay to the European Medicines Agency under the provisions of the EU pharmacovigilance legislation1,2. While the fees are critical to the EMA being able to fulfil its new responsibilities under the legislation, it could still be a couple of years before they are in place.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts